Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03809585 · ClinicalTrials.gov registry record
Observational Study of Iris Tumors
A clinical trial of Iris Tumor, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT03809585: Recruiting study of Iris Tumor, sponsored by Oregon Health and Science University.
NCT03809585 is a study of Iris Tumor that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03809585, a study of Iris Tumor, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Primary Outcome
OCT/OCTA will be used to compare tumor thickness measurements against the conventional Ultrasonic Biomicroscopy (UBM) device. Tumor thickness will be measured in millimeters, and growth of 0.5 mm or greater will be used to differentiate malignant from benign lesions.
Conditions Studied
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2027-12 |
What NCT03809585 shows while recruiting
NCT03809585 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Iris Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT03809585 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03809585 about?
NCT03809585 is a clinical study titled "Observational Study of Iris Tumors". This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
What is the current status of trial NCT03809585?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2018-06-20. Estimated completion is 2027-12.
What conditions does trial NCT03809585 study?
This clinical trial studies the following conditions: Iris Tumor.
Who is sponsoring clinical trial NCT03809585?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03809585 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI